Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?
Animals
Antibodies
/ administration & dosage
Biomarkers
Carcinoma, Hepatocellular
/ diagnostic imaging
Chemoembolization, Therapeutic
Contrast Media
/ administration & dosage
Gadolinium
/ administration & dosage
Liver
/ diagnostic imaging
Liver Neoplasms, Experimental
/ diagnostic imaging
Magnetic Resonance Imaging
/ methods
Male
Molecular Imaging
/ methods
Rabbits
Tumor Microenvironment
Journal
Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
8
7
2020
medline:
15
12
2020
entrez:
8
7
2020
Statut:
ppublish
Résumé
Background The immuno-metabolic interplay has gained interest for determining and targeting immunosuppressive tumor micro-environments that remain a barrier to current immuno-oncologic therapies in hepatocellular carcinoma. Purpose To develop molecular MRI tools to reveal resistance mechanisms to immuno-oncologic therapies caused by the immuno-metabolic interplay in a translational liver cancer model. Materials and Methods A total of 21 VX2 liver tumor-bearing New Zealand white rabbits were used between October 2018 and February 2020. Rabbits were divided into three groups. Group A (
Identifiants
pubmed: 32633675
doi: 10.1148/radiol.2020200373
pmc: PMC7434651
mid: NIHMS1609892
doi:
Substances chimiques
Antibodies
0
Biomarkers
0
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-583Subventions
Organisme : NCI NIH HHS
ID : R01 CA206180
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007205
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI089992
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034989
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB023366
Pays : United States
Références
Curr Opin Immunol. 2017 Jun;46:38-44
pubmed: 28458087
Clin Cancer Res. 2014 Dec 15;20(24):6406-17
pubmed: 25326230
Trends Cancer. 2017 Nov;3(11):797-808
pubmed: 29120755
Lancet. 2004 Jan 31;363(9406):357-62
pubmed: 15070565
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
J Am Chem Soc. 2012 Mar 7;134(9):3965-7
pubmed: 22339432
Biochem J. 1920 Oct;14(5):654-9
pubmed: 16742921
Int J Hyperthermia. 2018 Nov;34(7):934-942
pubmed: 29631466
Hepatology. 2016 Jul;64(1):106-16
pubmed: 26765068
Cancer Res. 2016 Mar 15;76(6):1381-90
pubmed: 26719539
Cell. 2017 May 4;169(4):570-586
pubmed: 28475890
Cancer Res. 2012 Jun 1;72(11):2746-56
pubmed: 22593198
Int J Clin Pract. 2014 May;68(5):609-17
pubmed: 24283303
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
Front Immunol. 2019 Jun 25;10:1402
pubmed: 31293576
Adv Exp Med Biol. 2017;1036:19-31
pubmed: 29275462
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
J Nucl Med. 2016 Oct;57(10):1487-1492
pubmed: 27469363
Nat Rev Immunol. 2014 Nov;14(11):719-30
pubmed: 25324123
Radiology. 2012 Aug;264(2):423-7
pubmed: 22570507
Clin Cancer Res. 2019 Jul 15;25(14):4202-4210
pubmed: 30804019
Radiology. 2019 Jan;290(1):198-206
pubmed: 30398435
Clin Cancer Res. 2020 Jan 15;26(2):428-438
pubmed: 31582517
Drug Dev Res. 2018 Dec;79(8):373-382
pubmed: 30343496
Magn Reson Med. 2020 May;83(5):1553-1564
pubmed: 31691371
Eur J Cancer. 2017 Dec;87:101-112
pubmed: 29145036
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Clin Cancer Res. 2019 May 15;25(10):3054-3062
pubmed: 30796036
Sci Rep. 2019 Mar 1;9(1):3260
pubmed: 30824840
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Theranostics. 2019 May 27;9(13):3674-3686
pubmed: 31281506
Int J Nanomedicine. 2017 Jul 26;12:5331-5343
pubmed: 28794626
Semin Cancer Biol. 2017 Apr;43:74-89
pubmed: 28267587
J Thorac Dis. 2019 Jan;11(1):35-38
pubmed: 30863564
Target Oncol. 2019 Apr;14(2):115-123
pubmed: 30805831